Dan Benjamin Teleman - 17 Jun 2026 Form 4 Insider Report for Nasus Pharma Ltd (NSRX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: NSRX
Reported as of: 17 Jun 2026
Net transaction value: +$20,305
SEC form: 4
Accepted by SEC: 22 Jun 2026, 07:12:42 UTC
Prior SEC filing: 22 Apr 2026
Next SEC filing: 29 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Dan Benjamin Teleman

Key filing fact

Dan Benjamin Teleman filed Form 4 for Nasus Pharma Ltd (NSRX) on 22 Jun 2026.

Key facts

This page summarizes Dan Benjamin Teleman's Form 4 filing for Nasus Pharma Ltd (NSRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Jun 2026, 07:12.

Change

Previous filing in this sequence was filed on 22 Apr 2026.
Current net transaction value: +$20,305.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002122500 Primary reporting owner

Teleman Dan Benjamin

Relationship: Chief Executive Officer, Director
Address: P.O. BOX 284, TEL-AVIV-YAFO, ISRAEL
Signature: /s/ Dan Benjamin Teleman
Signature date: 22 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NSRX transaction

Ordinary Shares

Purchase

Transaction value: $20,305
Shares: +6,550
Change %: +4.2%
Price: $3.10
Shares after: 163,541
Date: 17 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of: (i) 30,696 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.